Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States.
Islet Cell Laboratory, Baylor Scott & White Research Institute, Dallas, TX, United States.
J Gastrointest Surg. 2024 Aug;28(8):1309-1318. doi: 10.1016/j.gassur.2024.05.034. Epub 2024 Jun 2.
Total pancreatectomy with islet autotransplantation (TPIAT) is an effective treatment for patients with chronic pancreatitis (CP) when other interventions are unsuccessful. CP has many etiologies including heredity. Metabolic and pain relief outcomes after TPIAT are presented among patients with a genetic CP etiology compared with those with a nongenetic etiology in a large cohort of patients who underwent this procedure at our center.
A retrospective analysis was performed of 237 patients undergoing TPIAT between 2006 and 2023. We analyzed the differences in patients with genetic (n = 56) vs nongenetic CP etiologies (n = 181) in terms of pre-TPIAT factors including patient characteristics and disease state, results from the isolation process, and outcomes such as long-term glycemic and pain control.
Patients with genetic CP underwent TPIAT at a significantly younger age (32.3 vs 41.3 years nongenetic; P < .0001) and endured symptoms for a significantly longer period (10 vs 6 years; P < .01). A significantly lower mass of islets was isolated from patients with genetic CP (P < .01), which increased with body mass index in both groups. Despite lower yields, patients with genetic CP maintained metabolic function similar to patients with nongenetic CP, as indicated by insulin independence and C-peptide, blood glucose, and hemoglobin A1C levels after TPIAT. Post-transplant narcotic usage and pain scores significantly decreased compared with those before TPIAT, and more patients with genetic CP were pain free and narcotic free after TPIAT.
Our data validate TPIAT as a beneficial procedure for patients enduring CP of genetic etiology. Pain that is inevitably recurrent after minor interventions owing to the nature of the disease and favorable TPIAT outcomes should be considered in the decision to perform early TPIAT in cases of genetic CP.
全胰切除术伴胰岛自体移植(TPIAT)是治疗慢性胰腺炎(CP)患者的有效方法,当其他干预措施无效时,可采用这种方法。CP 有许多病因,包括遗传因素。本研究旨在对在我中心接受 TPIAT 的大样本患者队列中,比较具有遗传 CP 病因和非遗传病因患者 TPIAT 后的代谢和疼痛缓解结果。
对 2006 年至 2023 年间接受 TPIAT 的 237 例患者进行回顾性分析。我们分析了具有遗传(n=56)和非遗传 CP 病因(n=181)的患者在 TPIAT 前的差异,包括患者特征和疾病状态、分离过程的结果以及长期血糖和疼痛控制等结果。
遗传 CP 患者接受 TPIAT 的年龄明显较小(32.3 岁 vs 非遗传 CP 患者的 41.3 岁;P<0.0001),且症状持续时间明显更长(10 年 vs 6 年;P<0.01)。遗传 CP 患者分离的胰岛质量明显较低(P<0.01),但两组的胰岛质量均随体重指数的增加而增加。尽管产量较低,但遗传 CP 患者的代谢功能与非遗传 CP 患者相似,表现在 TPIAT 后胰岛素独立性和 C 肽、血糖和糖化血红蛋白水平。与 TPIAT 前相比,术后阿片类药物使用和疼痛评分显著降低,更多的遗传 CP 患者在 TPIAT 后无疼痛且无需使用阿片类药物。
我们的数据验证了 TPIAT 对具有遗传 CP 病因的患者是一种有益的治疗方法。在遗传 CP 患者中,由于疾病的性质,小的干预措施后必然会出现复发性疼痛,因此在决定早期进行 TPIAT 时应考虑到这一点。